IP Library Granted Patent US 8,383,794
Granted Patent B2
US 8,383,794 · App. 12/900,636 · Granted Feb 26, 2013

Conformation-selective nucleic acid inhibitors of AMPA glutamate receptors

Inventors: Li Niu (Loudonville, NY); Zhen Huang (Latham, NY)
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 8,383,794
App. No.
12/900,636
Granted
Feb 26, 2013
Kind
B2
Abstract

The present invention relates to novel nucleic acid ligands or aptamers that demonstrate potent and selective inhibition of the open-channel conformation of the α-amino-3-hydroxy-5-methyl-4-isoxazole propionate (AMPA) subtype of ionotropic glutamate receptors.

Claims (18)

1. A synthetic nucleic acid that binds to an open-channel conformation of a glutamate ion channel receptor, said nucleic acid comprising the nucleotide sequence of SEQ ID NO: 1.

2. The synthetic nucleic acid of claim 1 , comprising a nucleotide sequence selected from the group consisting of SEQ ID NO: 9, SEQ ID NO: 10, SEQ ID NO: 11, SEQ ID NO: 12, SEQ ID NO: 13 and SEQ ID NO: 14.

3. The synthetic nucleic acid of claim 1 , wherein the nucleic acid is RNA.

4. The synthetic nucleic acid of claim 1 , wherein the nucleic acid contains between 50 and 110 nucleotides.

5. The synthetic nucleic acid of claim 1 , wherein the nucleic acid contains between 56 and 100 nucleotides.

6. The synthetic nucleic acid of claim 1 , wherein said nucleic acid contains one or more chemically modified nucleotides.

7. The synthetic nucleic acid of claim 1 wherein the one or more chemically modified nucleotides has a 2′ fluoro substituent.

8. The synthetic nucleic acid of claim 1 , wherein said nucleic acid inhibits glutamate receptor function.

9. The synthetic nucleic acid of claim 1 , wherein said nucleic acid has a K I <1 μM.

10. A composition comprising a synthetic nucleic acid of claim 1 and further comprising one or more synthetic nucleic acids comprising one or more nucleotide sequences selected from the group consisting of SEQ ID NO: 2, SEQ ID NO: 3, SEQ ID NO: 4, SEQ ID NO: 5, SEQ ID NO: 6, and SEQ ID NO: 7.

11. The composition of claim 10 , wherein said synthetic nucleic acids have different nucleotide sequences.

12. The isolated nucleic acid of claim 1 wherein the glutamate receptor is of the α-amino-3-hydroxy-5-methyl-4-isoxazole propionic acid (AMPA) subtype.

13. A method of inhibiting the function of a glutamate receptor comprising contacting said receptor with a synthetic nucleic acid of claim 1 .

14. The method of claim 13 , wherein the glutamate receptor is of the AMPA subtype.

15. A method of inhibiting a glutamate receptor comprising contacting said receptor with the nucleic acid of claim 1 .

16. The method of claim 15 , wherein the glutamate receptor is of the AMPA subtype.

17. A pharmaceutical composition comprising a nucleic acid according to claim 1 and a pharmaceutically acceptable carrier.

18. An isolated DNA that codes for an RNA wherein the RNA comprises a nucleotide sequence selected from the group of SEQ ID NOS: 1 and 9 to 14.

Assignments (2)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Jan 23, 2013
From: NIU, LI; HUANG, ZHEN
To: THE RESEARCH FOUNDATION FOR THE STATE UNIVERSITY OF NEW YORK
Reel/Frame 029680/0105 →
CONFIRMATORY LICENSE Recorded Jan 14, 2011
From: STATE UNIVERSITY OF NEW YORK AT ALBANY
To: US ARMY, SECRETARY OF THE ARMY
Reel/Frame 025635/0847 →
Continuity (1)
Related Publication 20120088818A1 · Apr 12, 2012